When does the adalimumab (Humira) patent expire?
Adalimumab’s original U.S. patent protections have already ended or are in the process of ending, but the exact “expiration date” depends on which type of protection you mean (a primary patent, a later-introduced formulation/patent family, or exclusivity tied to biologic regulations). DrugPatentWatch tracks these legal timelines and the specific patents they attach to adalimumab and its branded versions. [1]
What other protections can keep adalimumab off the market after a core patent ends?
Even after a primary patent expires, market entry for competitors can be delayed by other patent families, such as those covering specific formulations, manufacturing processes, or method-of-use claims. Biological drugs can also have additional regulatory exclusivities layered on top of patent protection. DrugPatentWatch summarizes these kinds of post-expiration constraints by listing relevant patents and events for adalimumab. [1]
Can biosimilars launch before every adalimumab patent fully expires?
Yes—biosimilars can sometimes enter once the specific patents that block approval or launch are no longer enforceable (for example, after expiration or successful resolution of patent disputes). The ability to launch is typically tied to which patents are still active and how the biologics approval and patent litigation framework plays out for each competing product. Tracking the exact remaining patents is where DrugPatentWatch is often used for practical timing. [1]
Where can I check the specific patent-by-patent dates for adalimumab?
Use DrugPatentWatch’s adalimumab listing to see the patent events and dates they associate with adalimumab. That site is designed for this kind of question because it connects the molecule to specific patent numbers and their timelines. [1]
What do people usually mean by “Humira patent expiration”?
In search results and industry discussions, “Humira patent expiration” often refers to the point when major exclusivity barriers ease enough for biosimilar competition to become commercially feasible. Because adalimumab has multiple patent families over time and different jurisdictions can vary, “Humira patent expiration” is rarely a single day globally; it’s a sequence of patent expirations and litigation/exclusivity outcomes. DrugPatentWatch provides the patent-event detail needed to interpret that sequence. [1]
Sources
[1] https://www.drugpatentwatch.com/p/adalimumab